| NCT07053800 | Obe-cel in Severe, Refractory Systemic Lupus Erythematosus With Active Lupus Nephritis | NOT_YET_RECRUITING | PHASE2 | 2025-09 | 2030-02 | 2029-02 |
| NCT07139743 | Obe-cel in Refractory Progressive Forms of Multiple Sclerosis | RECRUITING | PHASE1 | 2025-08-04 | 2029-08-15 | 2029-08-15 |
| NCT06333483 | A Study of CD19 Targeted CAR T Cell Therapy in Patients With Severe, Refractory Systemic Lupus Erythematosus (SLE) | RECRUITING | PHASE1 | 2024-02-02 | 2026-12 | 2025-12 |
| NCT06173518 | A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) | RECRUITING | PHASE1 | 2023-11-16 | 2027-11 | 2027-11 |
| NCT04404660 | A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2020-06-03 | 2029-06-30 | 2029-06-30 |
| NCT03590574 | Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma | COMPLETED | PHASE1, PHASE2 | 2018-08-30 | 2024-12-12 | 2024-12-12 |
| NCT03628612 | Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells | ENROLLING_BY_INVITATION | PHASE2 | 2018-08-02 | 2043-12 | 2043-07 |
| NCT03287817 | Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma | TERMINATED | PHASE1, PHASE2 | 2017-09-05 | 2023-10-19 | 2023-10-19 |
| NCT03289455 | CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) | COMPLETED | PHASE1, PHASE2 | 2017-06-26 | 2020-05-18 | 2020-05-18 |
| NCT03287804 | APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma | TERMINATED | PHASE1, PHASE2 | 2017-05-05 | 2019-09-05 | 2019-09-05 |